Chinese net finance and economics on April 4 dispatch (reporter Du Ding) be in as the first A the enterprise of civilian battalion vaccine that appear on the market, zhi Feisheng content surrendered a bright key point 2018 " report " . Evening released on April 3 annals showed 2018, realize battalion to receive 5.228 billion yuan in those days, grow 289.43% compared to the same period; Net profit 1.451 billion yuan, grow 235.75% compared to the same period.
Harvest beautiful outstanding achievement however while, zhifei biologic share price goes low all the way however, not only appear below the circumstance that two city general went up on April 2 infrequent drop stop, now share price again low low go, dish in drop at most 8% the left and right sides.
It is reasonable that capital market polls with the foot, be in this " report " before releasing two days, zhi Feisheng content is weighing pound vaccine solely for its AC-Hib is triplex and vaccinal be faced with stop production and " make a heart unceasingly " . Annals shows, this vaccine is the component with the mainest profit of Zhi Feisheng content, corresponding last year production value achieves 1.352 billion yuan.
The data shows, zhi Feisheng content was handing in place greatly to hang out one's shingle in September 2010 appear on the market, one's early years sells name with vaccinal representative, april 2014, the AC-Hib vaccine of own research and development obtains green bamboo of Zhi Fei of its subsidiary Beijing medicines and chemical reagents registers batch of article, the 2nd quarter began to appear on the market 2015 sale. Ac-Hib is triplex and vaccinal basically use at preventing A group, C group the disease that bloodsucking bacili causes meningitis coccus and B flu.
Annals showed 2018, 2016, 2018, AC-Hib vaccine is approved sign and issue a quantity to be 222 thousand respectively, 4.704 million mix 6.437 million. If press AC-Hib vaccine 210 yuan / the price consideration that pay, 2017 the corresponding production value of AC-Hib 988 million yuan, corresponding 2018 production value achieves 1.352 billion yuan. Analysis of the personage inside course of study says, although sign and issue a quantity to not be equal to output and sale certainly, but average company foundation is vaccinal circumstance of sale, inventory, union is produced can plan with production, arrangement vaccine is approved sign and issue application, can regard as on certain level forecast vaccine of Zhi Feisheng content the index of follow-up sales volume, the price on union can understand the business income of breed roughly.
Recumbent sale AC-Hib is triplex the product such as vaccinal, acting HPV vaccine, nearly two years outstanding achievement shows Zhi Feisheng content saltant type grows. 2016-2018 year, biology of the Zhifei inside report period realizes battalion to receive 446 million yuan respectively, 1.343 billion yuan mix 5.228 billion yuan, net profit is 33 million yuan respectively, 432 million yuan mix 1.451 billion yuan.
Be in situation auspicious during, zhi Feisheng thing is unexpected in get into trouble. On April 1 afternoon, zhi Feisheng content gives out announcement to say, "On November 8, 2018, zhi Fei green bamboo feeds medical inspect bureau to submit the application that AC-Hib vaccine registers again to Beijing, up to now, administrative program is still half-baked, the company had be notted receive register again batch. In view of former medicines and chemical reagents period of efficacy of approval article date comes on April 1, 2019, accordingly, subsidiary is in did not obtain register again batch before, the production that suspends AC-Hib vaccine. the production that suspends AC-Hib vaccine..
Register again what is approving a reason that did not allot tardy? Does this vaccine occupy company whole battalion to close how old scale? Reporter of Chinese net finance and economics calls Dong Bi of Zhi Feisheng content, the phone cannot put through all the time. Although biology weighs Zhifei external, still have near 6 million stock up, should put quantity and annual was approved 2018 sign and issue a quantity to comparative. But its also admit, if this product obtains annotate on book no longer, will reach the management outstanding achievement henceforth to produce bigger effect 2019 to the company.
According to the calculating of Chinese industry website data shows, press 18 million new student, theoretic the demand of vaccine of Hib of 54 million agent is calculated, at present Hib vaccinal permeability is about 43.5% , AC-Hib is triplex and vaccinal take Hib vaccinal market 20.8% .
